Immunomodulatory drugs: Oral and systemic adverse effects

被引:104
作者
Bascones-Martinez, Antonio [1 ]
Mattila, Riikka [2 ]
Gomez-Font, Rafael [3 ]
Meurman, Jukka H. [2 ]
机构
[1] Univ Complutense Madrid, Sch Dent, Dept Med & Bucofacial Surg, E-28040 Madrid, Spain
[2] Univ Helsinki, Cent Hosp, Inst Dent, Dept Oral & Maxillofacial Dis, Helsinki 08200, Finland
[3] Univ Complutense Madrid, Dept Med & Bucofacial Surg, E-28040 Madrid, Spain
来源
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL | 2014年 / 19卷 / 01期
关键词
Immunomodulatory drugs; oral diseases; adverse effects; therapeutic action; INFLAMMATORY-BOWEL-DISEASE; PRIMARY SJOGRENS-SYNDROME; PLACEBO-CONTROLLED TRIAL; LUPUS-ERYTHEMATOSUS; LICHEN-PLANUS; B-CELL; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; RITUXIMAB TREATMENT; EFFICACY;
D O I
10.4317/medoral.19087
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives: The main objectives are to present the different adverses effects of the immunomodulatory drugs that can impair the quality of life of the immunosupressed patients and study the impact of immunomodualtion on oral diseases. Immunomodulatory drugs have changed the treatment protocols of many diseases where immune functions play a central role, such as rheumatic diseases. Their effect on oral health has not been systematically investigated, however. Study Design: We review current data on the new immunomodulatory drugs from the oral health perspective based on open literature search of the topic. Results: These target specific drugs appear to have less drug interactions than earlier immunomodulating medicines but have nevertheless potential side effects such as activating latent infections. There are some data showing that the new immunomodulatory drugs may also have a role in the treatment of certain oral diseases such as lichen planus or ameliorating symptoms in Sjogren's syndrome, but the results have not been overly promising. Conclusions: In general, data are sparse of the effect of these new drugs vs. oral diseases and there are no properly powered randomized controlled trials published on this topic.
引用
收藏
页码:E24 / E31
页数:8
相关论文
共 47 条
  • [1] Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?
    Andrews, J. M.
    Travis, S. P. L.
    Gibson, P. R.
    Gasche, C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (05) : 459 - 469
  • [2] Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients
    Aringer, Martin
    Houssiau, Frederic
    Gordon, Caroline
    Graninger, Winfried B.
    Voll, Reinhard E.
    Rath, Eva
    Steiner, Guenter
    Smole, Josef S.
    [J]. RHEUMATOLOGY, 2009, 48 (11) : 1451 - 1454
  • [3] Lichen planus-like eruptions: An emerging side effect of tumor necrosis factor-α antagonists
    Asarch, Adam
    Gottlieb, Alice B.
    Lee, Jin
    Masterpol, Katherine S.
    Scheinman, Pamela L.
    Stadecker, Miguel J.
    Massarotti, Elena M.
    Bush, Michelle L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 61 (01) : 104 - 111
  • [4] Asherson RA, 2008, J RHEUMATOL, V35, P1224
  • [5] Learning about the Safety of Drugs - A Half-Century of Evolution
    Avorn, Jerry
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (23) : 2151 - 2153
  • [6] Ben Dhaou Besma, 2012, Tunis Med, V90, P774
  • [7] Bowman SJ, 2012, CURR PHARM BIOTECHNO, V13, P1997
  • [8] Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
    Bradford, Kara
    Shih, David Q.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (37) : 4166 - 4173
  • [9] Issues Related to Clinical Trials of Oral and Biologic Disease-Modifying Agents for Sjogren's Syndrome
    Carsons, Steven E.
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2008, 34 (04) : 1011 - +
  • [10] Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid)
    Chan, Lawrence S.
    [J]. CLINICS IN DERMATOLOGY, 2012, 30 (01) : 34 - 37